Neuren Pharmaceuticals Ltd (ASX:NEU) is a biopharmaceutical company developing therapies for neurodevelopmental disorders caused by genetic abnormalities or brain injury. Incorporated in New Zealand and listed on the ASX, it earns Royalty Revenue from Acadia Pharmaceuticals for DAYBUE (trofinetide), the first approved treatment for Rett syndrome in the United States. Neuren is also developing NNZ-2591 (ercanetide) for several rare conditions. Jonathan Pilcher is CEO and Managing Director.

On 2 October 2026, Neuren shares were trading at $20.28, up 0.70%. The company reports on a calendar-year basis, and its half-year results to 30 June 2026 introduced its first Dividend policy.

Recent Developments

On 25 August 2026, Neuren released its Appendix 4D and interim report for the half-year ended 30 June 2026. Key figures include:

  • Revenues from ordinary activities were A$42.7 million, up 8%.
  • Royalty income from Acadia for DAYBUE was US$23.3 million (A$33.2 million), up 29% in US dollars.
  • Profit after tax was A$4.9 million, compared with A$15.0 million, as Research and Development costs rose by A$12.5 million to A$27.4 million.
  • Total cash and short-term investments were A$286.5 million.
  • Neuren introduced its first dividend policy and declared a fully franked Interim Dividend of 15.0 cents per share, with an ex-dividend date of 15 September, Record Date of 16 September and payment date of 7 October 2026.
  • The company bought back 315,550 shares for $3.9 million.

DAYBUE net sales in H1 2026 were US$226.0 million, up 25%. A new powder formulation, DAYBUE STIX, became broadly available in the US in Q2 2026, and by 30 June 40% of US patients were receiving STIX. Acadia raised its full-year 2026 DAYBUE net sales guidance to US$480 million to US$510 million, lifting Neuren's anticipated royalties to US$53 million to US$56 million. The next North American milestone of US$50 million is payable when annual net sales in North America exceed US$500 million. In Europe, the European Commission granted Marketing authorisation for trofinetide, with a German launch anticipated in early Q4 2026 and a potential US$35 million milestone on first commercial sale.

For NNZ-2591, the Phase 3 Koala trial in Phelan-McDermid syndrome began dosing in February 2026, with 15 sites activated. An FDA meeting on Pitt Hopkins syndrome is scheduled for late October 2026, and the IND for hypoxic ischemic encephalopathy is now expected in H1 2027 after the FDA requested an additional animal study.

Other income included interest income of A$5.6 million and a foreign currency gain of A$4.0 million, while the company recognised a loss of A$4.7 million on forward contracts. Corporate and administration costs were A$3.0 million. Net cash from Operating Activities was A$8.0 million, compared with A$128.3 million in the prior period, which had included a large milestone receipt. A recent study supported by Neuren estimated Phelan-McDermid syndrome prevalence at 1 in 7,300 people. The US Rare Pediatric Disease Priority Review Voucher program was reauthorised to 30 September 2029, and Neuren holds rare pediatric disease designations for NNZ-2591 in three conditions, which could qualify it for a voucher upon approval.

Sector Context

Rare disease Drug Development has attracted significant investment, supported by regulatory incentives such as Orphan Drug designation, fast track status and priority review vouchers. Companies that license products to larger partners can earn royalties and milestone payments without bearing full commercialisation costs.

Neurodevelopmental disorders such as Rett syndrome and Phelan-McDermid syndrome have limited treatment options, creating significant unmet need. However, Clinical Trials in these conditions can be complex, with challenges in patient recruitment and measuring outcomes. Royalty income depends on the commercial success of partners' products.

Licensing arrangements with tiered royalties mean that royalty rates can rise as sales grow. Neuren's royalty rate on North American DAYBUE sales increases from 10% to 12% for annual net sales above US$250 million and to 14% above US$500 million. International launches in Europe and Japan could add further royalties and milestone payments.

Rett syndrome is a rare neurodevelopmental disorder that mainly affects girls, and DAYBUE was the first treatment approved for the condition in the US. Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome are other rare genetic conditions with limited treatment options, which is why regulators offer incentives for developers. Priority review vouchers awarded on approval can be sold for significant sums, as shown by a recent sale for US$215 million.

Risks and Uncertainties

Neuren's revenue depends almost entirely on DAYBUE sales by Acadia, so any slowdown in sales or competition could affect royalties. NNZ-2591 trials may not succeed, and regulatory feedback has already delayed the HIE program. Rising R&D costs have reduced profit. Currency movements between the US and Australian dollars affect reported results. The new dividend policy depends on continued royalty growth.

Delays in FDA feedback, as experienced with the HIE program, can push back development timelines. The company has commitments of about $57.9 million under product development contracts.

The company noted that its Pitt Hopkins trial design is subject to discussion with the FDA, and the outcome of that meeting is uncertain.

Catalysts Investors Can Watch

Investors may watch for the DAYBUE launch in Germany and the potential US$35 million milestone, progress toward the US$50 million North American milestone, the FDA meeting on Pitt Hopkins syndrome, enrolment in the Koala trial, and Japan trial results expected in September to November 2026.

Progress on the share buy-back program, which allows the repurchase of up to 5% of shares, may also be followed.

Key Takeaways

Neuren's half-year result showed growing royalties and the introduction of a first dividend, alongside increased Investment in NNZ-2591. DAYBUE growth and clinical progress are the main factors to follow.